A patient receiving transurethral alprostadil asks about intracavernous administration. Which information would be included in the explanation?

Questions 265

ATI RN

ATI RN Test Bank

ATI Pharmacology Across the Lifespan Questions

Question 1 of 5

A patient receiving transurethral alprostadil asks about intracavernous administration. Which information would be included in the explanation?

Correct Answer: A

Rationale: Transurethral alprostadil has fewer side effects (e.g., less priapism or fibrosis) compared to intracavernous injections, though both increase penile arterial flow. Intracavernous doses are lower (5-40 mcg vs. 125-1000 mcg transurethrally), and volume isn’t 0.1 mL, making option A the key distinction to explain.

Question 2 of 5

Patient teaching for a patient being discharged on a beta blocker includes which statement?

Correct Answer: A

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Question 3 of 5

A nurse should report which of the following as an adverse effect of ciprofloxacin?

Correct Answer: C

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Question 4 of 5

Which of the following drugs is most immediately helpful in treating a severe acute asthma attack?

Correct Answer: C

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Question 5 of 5

Lab results reveal that 82-year-old male with type 2 diabetes has a HgbA1C of 10.9%. He is presently taking glipizide (Glucotrol). In addition to his type 2 diabetes, he has renal insufficiency and moderate cardiac ischemi Which of the following interventions is most appropriate for management of the patient’s diabetes?

Correct Answer: A

Rationale: Failed to generate a rationale of 500+ characters after 5 retries.

Access More Questions!

ATI RN Basic


$89/ 30 days

ATI RN Premium


$150/ 90 days

Similar Questions